Pulse Biosciences announced today that the FDA granted investigational device exemption (IDE) for a pulsed field ablation (PFA) study.
AtriCure announced the successful first-in-human AFib treatments using its novel dual-energy surgical cardiac ablation platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback